Iprixon Neb

Ipratropium bromide, the active ingredient in Iprixon Neb, is a bronchodilator (Anticholinergic + Short‑acting β2‑agonist) presented as a nebulizer solution for inhalation use. It treats chronic obstructive pulmonary disease (COPD) and acute bronchospasm in asthma patients. GNH USA supplies Iprixon Neb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iprixon Neb combines ipratropium bromide and salbutamol to provide bronchodilation in obstructive airway diseases.

- Chronic obstructive pulmonary disease (COPD): improves airflow and reduces dyspnea. - Asthma (acute bronchospasm): rapidly relieves bronchoconstriction during attacks. - Bronchospasm associated with other respiratory conditions: helps restore airway patency when sudden narrowing occurs.

Adverse reactions may occur with inhalation of Iprixon Neb.

Common Side Effects: - Cough or throat irritation - Dry mouth - Tremor or shakiness - Headache - Nausea or mild gastrointestinal upset - Dizziness

Serious or Rare Side Effects: - Paradoxical bronchospasm - Angioedema or severe allergic reaction - Tachycardia or arrhythmia - Significant hypotension - Hyperglycemia in susceptible individuals - Severe respiratory distress requiring medical attention

Use Iprixon Neb with clinical judgment and monitor patients for specific concerns.

- Cardiac assessment: evaluate for underlying heart disease before initiating therapy. - Monitor for paradoxical bronchospasm: discontinue if symptoms worsen. - Caution in glaucoma: anticholinergic effect may increase intra‑ocular pressure. - Adjust in renal impairment: consider reduced clearance of ipratropium. - Hypersensitivity: avoid in patients with known allergy to either component. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Iprixon Neb may interact with other medications; review patient medication lists.

Major Interactions (Avoid): - Non‑selective beta‑blockers: may blunt bronchodilator response. - Monoamine oxidase inhibitors (MAOIs): risk of exaggerated cardiovascular effects. - Other anticholinergic agents: additive anticholinergic burden.

Moderate Interactions (Monitor Closely): - Diuretics: potential hypokalemia may enhance salbutamol‑induced tachyarrhythmias. - Theophylline: increased risk of central nervous system stimulation. - ACE inhibitors: may increase incidence of cough when combined with inhaled agents.